Blue Skies: Merck Looks For Chronic Pain Candidates In Australia
This article was originally published in PharmAsia News
In a deal described as “out of the blue” by Australian biotech Bionomics, Merck has acquired an option to license a small molecule for up to $172 million in fees and milestones as part of a two-year research program focused on chronic pain treatments.
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.